Skip to main content
Premium Trial:

Request an Annual Quote

Genomics One Closes $500K Private Placement to Finance BioDefense Operations

NEW YORK, June 3 (GenomeWeb News) - Genomics One announced today a $500,000 private placement financing for its biodefense operations.

 

Genomics One CEO Suzanne Lebel will sell to Wyntrust Ventures Capital 1.2 million common shares of Genomics One stock at a price of $.23 per share for gross proceeds of $272,727. In addition, a second investor will subscribe 1 million common shares at $.23 per share for gross proceeds of $227,273.

 

The transaction is subject to TSX Venture Exchange approval, and is expected to close on or about June 8.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.